Cipla, a Rs.6,800 crore plus pharma major, has posted impressive financial performance during the second quarter ended September 2012. Its net profit went up by 61.8 per cent to Rs.500 crore from Rs.309 crore in the corresponding period of last year. Its EBDITA also moved up by 60.4 per cent to Rs.741 crore from Rs.462 crore. With significant growth in profits, its earnings per share for the quarter increased to Rs.6.23 from Rs.3.85 in the last period.
The company's net sales increased by 23.9 per cent to Rs.2,146 crore from Rs.1,732 crore in the similar period of last year. Its domestic revenues grew by 13.5 per cent to Rs.962 crore from Rs.847 crore primarily due to anti-asthma, anti-biotics and cardiovascular therapy segments. Its exports increased by 38.2 per cent to Rs.1,029 crore from Rs.752 crore. Exports of APIs grew by 9 per cent to Rs.174 crore from Rs.159 crore in the corresponding quarter of last year. Formulation business worked out to 91 per cent of total sales and API business 9 per cent.
For the first half ended September 2012, Cipla's net sales increased by23.8 per cent to Rs.4,063 crore from Rs.3,282 crore in the similar period of last year. Its EBDITA moved up by 54.4 per cent to Rs.1,334 crore from Rs.864 crore and net profit by 60.3 per cent to Rs.901 crore from Rs.562 crore. Its formulations sales for the first half increased by 31.1 per cent to Rs.1849 crore from Rs.1,410 crore and that of APIs grew by 3.5 per cent to Rs.342 crore.